IRCT20161215031429N3 IRCT 2018-10-02 Tabriz University of Medical Sciences The effect of probiotics on allergic rhinitis and asthma The effects of probiotic on clinical findings in patients with allergic rhinitis and asthma 2018-10-07 anticipated 30 Complete https://irct.ir/trial/24724 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: After the primary visit, the participants who meet the inclusion criteria will be allocated by randomization software into two groups. The random allocation will be done through blocks of size 8 in order to make balance in number between male and female, Blinding description: After signing informed consent by all participants, the participants will be numbered by a tertiary investigator and the numbers will be entered to the randomization software. After allocating the participants to the two groups by randomization software, the case and control groups will be determined. Then the supplements and placebo will be given to the secondary investigator, who is blind to the sequence of entering to the study. Finally, the supplements and placebo will be given to the patients of each group which is determined by the tertiary investigator who is not aware of the content of the capsules. 3 Condition 1: Asthma. Condition 2: Allergic Rhinitis. Intervention 1: Intervention group: Familact probiotic capsules produced by Zist Takhmir Co. (Tehran, Iran) will be administered to patients with asthma and allergic rhinitis for 8 weeks, along with routine therapeutic treatment. Intervention 2: Control group: Placebo capsules produced by Zist Takhmir Co. (Tehran, Iran) will be administered to patients with asthma and allergic rhinitis for 8 weeks, along with routine therapeutic treatment. No - There is not a plan to make this available Justification or reason for not sharing IPD is No more information